مقالات پذیرفته شده در پنجمین کنگره بین المللی زیست پزشکی
Advances in viral therapy in human cancers
Advances in viral therapy in human cancers
Piruz Shadbash,1Seyed Reza Mohebbi,2,*Seyed Masoud Hosseini,3Seyed Amirmohammad Seyed Mirzajani,4Shabnam Kazemian,5Hamid Asadzadeh-Aghdaei,6
1. Basic and Molecular Epidemiology of Gastrointestinal Disorders Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences 2. Research Center for Gastroenterology and Liver Diseases, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran 3. Department of Microbiology and Microbial Biotechnology, Faculty of Life Sciences and Biotechnology, Shahid Beheshti University, Tehran, Iran 4. Basic and Molecular Epidemiology of Gastrointestinal Disorders Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences 5. Research Center for Gastroenterology and Liver Diseases, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran 6. Basic and Molecular Epidemiology of Gastrointestinal Disorders Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Introduction: In recent years, oncolytic virus therapy has appeared as a promising anti-cancer treatment. The idea of using viruses as a cancer therapy was formed in the 1950s. Oncolytic virotherapy is discussed as a key factor in modern immunotherapy. Oncolytic viruses selectively replicate in cancer cells and destroy them without damaging normal cells. Oncolytic viruses invade and activate tumor immune cells by promoting the release of large amounts of tumor antigens and cytokines.
Methods: Although, there are multiple challenges to exploiting the potential of oncolytic viruses, like the lack of biomarkers for accurate treatment, the difficulty of systemic administration due to the presence of neutralizing antibodies in popular oncolytic viral vectors in human serum.
Results: Many cancer patients have been treated with oncolytic viral drugs that are administered in almost every possible route, and some have developed tumor regression at various times. The M1 strain, isolated in the 1960s on the Chinese island of Hainan, belongs to the alphavirus genus Togaviridae family.
Conclusion: During the development of the M1 virus, many challenges have been addressed and numerous biomarkers have been recognized for accurate treatment. Systemic administration of M1 is appropriate due to the very low percentage of neutralizing antibodies in the general population.